Investigating the effects of renal nerve denervation on kidney function
Effect of RDN on Renal Function
This study is testing if a procedure called renal nerve denervation can improve kidney function in adults with high blood pressure who haven't had success with other medications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | The First Affiliated Hospital of Xiamen University Academic / other |
| Locations | 1 site (Xiamen, Fujian) |
| Trial ID | NCT05612906 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the impact of renal nerve denervation (RDN) on renal function in patients with hypertension. It will include individuals aged 18 to 75 who have essential hypertension or related conditions and have not responded adequately to multiple antihypertensive medications. The study will assess renal function before and after the RDN procedure to determine its safety and efficacy. Participants will be required to provide informed consent and meet specific inclusion criteria.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 75 with resistant hypertension who are willing to undergo renal nerve denervation.
Not a fit: Patients with secondary hypertension, severe systemic diseases, or unsuitable renal arteries for ablation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the safety of RDN and its potential to improve kidney function in hypertensive patients.
How similar studies have performed: While RDN has shown promise in treating hypertension, the specific effects on renal function are still being explored, making this study a valuable addition to existing research.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
1.18\<age≤75 years; 2.clinic blood pressure ≥ 140/90 mmHg or 24-hour ambulatory blood pressure monitoring average blood pressure ≥ 135/85 mmHg after taking 3 or more antihypertensive drugs for more than 4 weeks; 3.essential hypertension, renal parenchymal hypertension, or hypertension patients who are willing to receive RDN ; 4.who signed informed consent and were approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University.
Exclusion Criteria:
* pregnant women or lactating patients;
* identified secondary hypertension or Pseudo hypertension;
* whose renal arteries were unsuitable for ablation
* obvious bleeding tendency and blood system diseases;
* malignant tumors or end-stage diseases; ⑥Severe peripheral vascular disease, abdominal aortic aneurysm; ⑦A history of the acute coronary syndrome within two weeks; ⑧acute or severe systemic infection; ⑨drug or alcohol dependence or refusal to sign informed consent.
Where this trial is running
Xiamen, Fujian
- zhengrong Huang — Xiamen, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Zhengrong Huang, M.D.
- Email: huangzhengrong@xmu.edu.cn
- Phone: +8613606028353
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.